荣昌生物制药（烟台）股份有限公司

活动与演示文稿

请选择年度

●2026
●2025
●2024
●2023
●2022
●2021

筛选清空

2026 EULAR：Efficacy and safety of Telitacicept in patients with Sjögren’s disease 下载
RCTS_2026_ASCO:Disitamab vedotin (RC48), Tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated survival and exploratory biomarker results from the RCTS trial 下载
Abstract TPS4245_2026 ASCO：Efficacy and safety of disitamab vedotin (DV) combined with trastuzumab, and tislelizumab versus chemotherapy (CAPOX) combined with trastuzumab ± pembrolizumab for patients with first-line HER2-high advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA): a randomized controlled phase 3 trial 下载
Abstract LBA4026_2026 ASCO：Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (Chemo)/trastuzumab (Tra) for first-line (1L) HER2- expressing locally advanced or metastatic (la/m) gastric cancer (GC): Updated results from the RC48-C027 trial 下载
Abstract 598 2026 ASCO：Efficacy and safety of neoadjuvant disitamab vedotin (DV) in combination with toripalimab (Tor) and concurrent/sequential chemotherapy (chemo) in patients with HR-negative, HER2-low breast cancer: A randomized multicenter phase 2 study 下载
荣昌生物 2025年年度报告下载
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the phase II RC48-C017 trial: updated results 下载
2026 ASCO-GU | RC48-C017研究数据更新，维迪西妥单抗联合免疫新辅助治疗膀胱癌带来持久生存获益下载
JP Morgan Healthcare Conference 下载
泰它西普治疗眼肌型重症肌无力（OMG） Ⅲ期临床研究实现首例患者入组下载

< 1/8 >